136 related articles for article (PubMed ID: 37863181)
41. Watch-and-Wait Approach to Rectal Cancer: The Role of Imaging.
Jayaprakasam VS; Alvarez J; Omer DM; Gollub MJ; Smith JJ; Petkovska I
Radiology; 2023 Apr; 307(1):e221529. PubMed ID: 36880951
[TBL] [Abstract][Full Text] [Related]
42. [Diagnosis and treatment strategy for clinical complete responders after chemoradiotherapy for rectal cancer: is watch-and-wait policy safe?].
Yao HW; Liu YH
Zhonghua Wai Ke Za Zhi; 2017 Jul; 55(7):496-499. PubMed ID: 28655076
[TBL] [Abstract][Full Text] [Related]
43. A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.
Vatandoust S; Wattchow D; Sposato L; Michael MZ; Leung J; Gormly K; Chen G; Symonds EL; Tie J; Papanicolas LE; Woods S; Gebski V; Mead K; Kuruni A; Karapetis CS
BMC Cancer; 2022 Mar; 22(1):222. PubMed ID: 35232427
[TBL] [Abstract][Full Text] [Related]
44. Selected stage IV rectal cancer patients managed by the watch-and-wait approach after pelvic radiotherapy: a good alternative to total mesorectal excision surgery?
Custers PA; Hupkens BJP; Grotenhuis BA; Kuhlmann KFD; Breukink SO; Beets GL; Melenhorst J;
Colorectal Dis; 2022 Apr; 24(4):401-410. PubMed ID: 35060263
[TBL] [Abstract][Full Text] [Related]
45. Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy.
Gao Z; Zhu Z; Li K
J Clin Oncol; 2024 Mar; 42(9):1088. PubMed ID: 38306588
[No Abstract] [Full Text] [Related]
46. A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management.
Weiser MR; Chou JF; Kim JK; Widmar M; Wei IH; Pappou EP; Smith JJ; Nash GM; Paty PB; Cercek A; Saltz LB; Romesser PB; Crane CH; Garcia-Aguilar J; Schrag D; Gönen M
JAMA Netw Open; 2022 Sep; 5(9):e2233859. PubMed ID: 36173634
[TBL] [Abstract][Full Text] [Related]
47. Interpretation of the OPRA Study: Are Our Criteria Reliable Enough to Recommend Watch and Wait?
Sütcüoğlu O; Rustamova Cennet N; Özet A; Özdemir N; Yazıcı O
J Clin Oncol; 2023 Jan; 41(2):416-417. PubMed ID: 36126234
[No Abstract] [Full Text] [Related]
48. Is the watch-and-wait strategy suitable for every patient who has achieved a complete clinical response with neoadjuvant treatment in locally advanced rectum cancer?
Akturk Esen S; Uncu D
J Surg Oncol; 2024 Mar; 129(3):459-460. PubMed ID: 38031877
[No Abstract] [Full Text] [Related]
49. Outcome and Salvage Surgery Following "Watch and Wait" for Rectal Cancer after Neoadjuvant Therapy: A Systematic Review.
Kong JC; Guerra GR; Warrier SK; Ramsay RG; Heriot AG
Dis Colon Rectum; 2017 Mar; 60(3):335-345. PubMed ID: 28177997
[TBL] [Abstract][Full Text] [Related]
50. From Clinical Trials to Practice: Anticipating and Overcoming Challenges in Implementing Watch-and-Wait for Rectal Cancer.
Loria A; Ramsdale EE; Aquina CT; Cupertino P; Mohile SG; Fleming FJ
J Clin Oncol; 2024 Mar; 42(8):876-880. PubMed ID: 38315943
[No Abstract] [Full Text] [Related]
51. Near-complete response following neoadjuvant therapy in rectal cancer: wait a bit longer?
Beets GL
Br J Surg; 2023 Jul; 110(8):938-939. PubMed ID: 37364285
[No Abstract] [Full Text] [Related]
52. Cost-Effectiveness of Watch and Wait: What is in the Box of this Organ-Preservation Strategy?
Perez RO
Ann Surg Oncol; 2022 Mar; 29(3):1516-1517. PubMed ID: 34997413
[No Abstract] [Full Text] [Related]
53. "Watch and wait" approach in rectal cancer patients following complete clinical response to neoadjuvant chemoradiotherapy does not compromise oncologic outcomes.
Neşşar G; Demirbağ AE; Mısırlıoğlu HC; Sezer S
Turk J Gastroenterol; 2019 Nov; 30(11):951-956. PubMed ID: 31767549
[TBL] [Abstract][Full Text] [Related]
54. Expanding the utility of the watch-and-wait approach to stage IV patients: Results from the Dutch consortium.
Kazi M; Saklani A
Colorectal Dis; 2022 Jul; 24(7):876-877. PubMed ID: 35258147
[No Abstract] [Full Text] [Related]
55. [Current status and perspectives on "watch and wait" strategy for rectal cancer patients after clinical complete response following neoadjuvant chemoradiation].
Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):521-526. PubMed ID: 31238632
[TBL] [Abstract][Full Text] [Related]
56. Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis.
Li J; Ma Y; Wen L; Zhang G; Yao X
Expert Rev Anticancer Ther; 2023 May; 23(5):555-564. PubMed ID: 36795784
[TBL] [Abstract][Full Text] [Related]
57. Protocol for a national audit of the watch-and-wait approach in patients with rectal cancer in Aotearoa New Zealand: The ACCORD study.
STRATA Collaborative
Colorectal Dis; 2024 Feb; 26(2):371-379. PubMed ID: 38124235
[TBL] [Abstract][Full Text] [Related]
58. Organ Preservation in Rectal Cancer.
Yuval JB; Thompson HM; Garcia-Aguilar J
J Gastrointest Surg; 2020 Aug; 24(8):1880-1888. PubMed ID: 32314234
[TBL] [Abstract][Full Text] [Related]
59. "Watch and Wait" for complete clinical response after neoadjuvant chemoradiotherapy for rectal cancer.
Peacock O; Chang GJ
Minerva Chir; 2019 Dec; 74(6):481-495. PubMed ID: 31580047
[TBL] [Abstract][Full Text] [Related]
60. The utility of short-course radiotherapy in a watch-and-wait strategy for rectal cancer - the need to measure the interval to tumour response assessment from the radiation start.
Pietrzak L; Cencelewicz A; Rutkowski A; Hołdakowska A; Paciorek K; Jankowski M; Zegarski W; Reszke J; Wawok P; Richter P; Małecki K; Szelachowska J; Bębenek M; Gisterek I; Jankiewicz M; Michalski W; Socha J; Zółciak-Siwińska A; Bujko K;
Acta Oncol; 2022 Sep; 61(9):1121-1125. PubMed ID: 36200928
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
